{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:01:58Z","timestamp":1793750518337,"version":"4.6.1"},"reference-count":14,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015751","name":"Qu\u00e9bec Consortium for Drug Discovery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000971","name":"ALS Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009017","name":"ALS Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000406","name":"Motor Neurone Disease Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>\n                    Optineurin (OPTN) is a multifunctional cytoplasmic adaptor protein implicated in maintaining neuronal homeostasis through its roles in selective autophagy, vesicle trafficking, and regulation of inflammatory signaling. Mutations in the\n                    <ns3:italic>OPTN<\/ns3:italic>\n                    gene are causally linked to several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and primary open-angle glaucoma. Here we have eight optineurin commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While the use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.\n                  <\/ns3:p>","DOI":"10.12688\/f1000research.169966.1","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:35:13Z","timestamp":1763663713000},"page":"1137","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A guide to selecting high-performing antibodies for Optineurin (UniProt ID: Q96CV9) for use in western blot, immunoprecipitation, and immunofluorescence"],"prefix":"10.12688","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3728-3158","authenticated-orcid":false,"given":"Vera Ru\u00edz","family":"Mole\u00f3n","sequence":"first","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham","family":"Ayoubi","sequence":"additional","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4611-6134","authenticated-orcid":false,"given":"Charles","family":"Alende","sequence":"additional","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Fothouhi","sequence":"additional","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Ryan","sequence":"additional","affiliation":[{"name":"Advanced BioImaging Facility Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-8281","authenticated-orcid":false,"given":"Sara Gonz\u00e1lez","family":"Bol\u00edvar","sequence":"additional","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-5473","authenticated-orcid":false,"given":"Donovan","family":"Worrall","sequence":"additional","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Durcan","sequence":"additional","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire M","family":"Brown","sequence":"additional","affiliation":[{"name":"Advanced BioImaging Facility Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7535-8718","authenticated-orcid":false,"given":"Vincent","family":"Francis","sequence":"additional","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"McPherson","sequence":"additional","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5906-025X","authenticated-orcid":false,"given":"Carl","family":"Laflamme","sequence":"additional","affiliation":[{"name":"Neuroscience and Neurosurgery Montreal Qu\u00e9bec McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3389\/fimmu.2018.01024","article-title":"Optineurin: A Coordinator of Membrane-Associated Cargo Trafficking and Autophagy.","volume":"9","author":"T Ryan","year":"2018","journal-title":"Front. Immunol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"114157","DOI":"10.1016\/j.bcp.2020.114157","article-title":"The diverse role of optineurin in pathogenesis of disease.","volume":"180","author":"Q Guo","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"73-85","DOI":"10.1080\/15548627.2021.1908722","article-title":"Emerging views of OPTN (optineurin) function in the autophagic process associated with disease.","volume":"18","author":"Y Qiu","year":"2022","journal-title":"Autophagy."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1522073","DOI":"10.3389\/fnagi.2025.1522073","article-title":"Optineurin overexpression ameliorates neurodegeneration through regulating neuroinflammation and mitochondrial quality in a murine model of amyotrophic lateral sclerosis.","volume":"17","author":"S Zhao","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2377-2383","DOI":"10.1002\/acn3.50928","article-title":"Novel mutation in optineurin causing aggressive ALS+\/-frontotemporal dementia.","volume":"6","author":"S Feng","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"12708","DOI":"10.1038\/ncomms12708","article-title":"Structural insights into the interaction and disease mechanism of neurodegenerative disease-associated optineurin and TBK1 proteins.","volume":"7","author":"F Li","year":"2016","journal-title":"Nat. Commun."},{"key":"ref7","article-title":"A consensus platform for antibody characterization.","author":"R Ayoubi","year":"2024","journal-title":"Nat. Protoc."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.12688\/f1000research.141719.1","article-title":"YCharOS open antibody characterisation data: Lessons learned and progress made.","volume":"12","author":"M Biddle","year":"2023","journal-title":"F1000Res."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7554\/eLife.48363","article-title":"Implementation of an antibody characterization procedure and application to the major ALS\/FTD disease gene C9ORF72.","volume":"8","author":"C Laflamme","year":"2019","journal-title":"elife."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.12688\/f1000research.124632.1","article-title":"Identification of highly specific antibodies for Serine\/threonine-protein kinase TBK1 for use in immunoblot, immunoprecipitation and immunofluorescence.","volume":"11","author":"W Alshafie","year":"2022","journal-title":"F1000Res."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7554\/eLife.91645.2","article-title":"Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications.","volume":"12","author":"R Ayoubi","year":"2023","journal-title":"elife."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"D358-D367","DOI":"10.1093\/nar\/gkac927","article-title":"The Antibody Registry: ten years of registering antibodies.","volume":"51","author":"A Bandrowski","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"25-38","DOI":"10.7171\/jbt.18-2902-002","article-title":"The Cellosaurus, a Cell-Line Knowledge Resource.","volume":"29","author":"A Bairoch","year":"2018","journal-title":"J. Biomol. Tech."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"100-106","DOI":"10.1038\/s41592-020-01018-x","article-title":"Cellpose: a generalist algorithm for cellular segmentation.","volume":"18","author":"C Stringer","year":"2021","journal-title":"Nat. Methods."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/14-1137\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/14-1137\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/14-1137\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:49:16Z","timestamp":1779875356000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/14-1137\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":14,"URL":"https:\/\/doi.org\/10.12688\/f1000research.169966.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.187366.r440395","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.187366.r425570","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.187366.r425570","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.187366.r440395","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/14-1137\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.187366.r440395, Deborah Moshinsky, Institute for Protein Innovation, Boston, Massachusetts, 30 Dec 2025, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/14-1137\/v1#referee-response-440395","order":0,"name":"referee-response-440395","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.187366.r425570, Andrew Buchanan, AstraZeneca, Cambridge, 17 Feb 2026, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/14-1137\/v1#referee-response-425570","order":1,"name":"referee-response-425570","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported in part by a grant from the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada. This work was also supported by the Government of Canada through Genome Canada, Genome Quebec, and Ontario Genomics (grant no. OGI-210). RA is supported by a Mitacs fellowship.\r\nThis work was supported by the CQDM (by a grant from the Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de\r\nl\u2019\u00c9nergie du Qu\u00e9bec). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}